Emerging therapeutics for ocular surface disease

Bielory, Brett P.; Shah, Steven P.; O’Brien, Terrence P.; Pérez, Víctor L.; Bielory, Leonard

doi:10.1097/aci.0000000000000309

Cited by 15 publications

(32 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small LFA-1 antagonist called Lifitegrast (SAR 1118) demonstrated in phase III clinical trials to significantly and safely relieve DES symptoms ( 39 ). Lifitegrast acts as an antagonist to LFA-1, resulting in the inhibition of T-cell activation, migration, and proliferation ( 40 ). However, other parameters to assess ocular function, such as Schirmer’s test results, tear breakup time, and inferior corneal staining, did not improve significantly ( 41 ).…”

Section: Current Therapeutic Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

et al. 2018

View full text Add to dashboard Cite

Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

show abstract

Section: Current Therapeutic Strategiesmentioning

confidence: 99%

“…However, other parameters to assess ocular function, such as Schirmer’s test results, tear breakup time, and inferior corneal staining, did not improve significantly ( 41 ). In July 2016, Xiidra ® was the first United States Food and Drug Administration (US-FDA)-approved LFA-1 agonist for treating DES ( 40 ).…”

Section: Current Therapeutic Strategiesmentioning

confidence: 99%

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Paradoxically, not only a suppressed immune system but also an overactive immune system can allow a commensal to behave as a pathobiont, resulting in a similar phenotype. While under conditions of immune homeostasis an IL‐17 response is beneficial and protects from pathogens, in models of DED and various forms of keratitis, IL‐17 is highly pathogenic, and its neutralization by antibodies or suppression by corticosteroids or mTOR inhibitors leads to the alleviation of the characteristic symptoms of disease . Data from animal models have suggested that in these diseases adaptive CD4 + T cells are primed against a self or unknown antigen in the draining lymph node to produce IL‐17, migrate to the eye, and cause tissue destruction .…”

Section: Can Ocular Commensals Become Pathobionts?mentioning

confidence: 99%

Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease

Leger

Caspi

2018

BioEssays

View full text Add to dashboard Cite

Until recently, the ocular surface is thought by many to be sterile and devoid of living microbes. It is now becoming clear that this may not be the case. Recent and sophisticated PCR analyses have shown that microbial DNA-based “signatures” are present within various ethnic, geographic, and contact lens wearing communities. Furthermore, using a mouse model of ocular surface disease, we have shown that the microbe, Corynebacterium mastitidis (C. mast), can stably colonize the ocular mucosa and that a causal relationship exists between ocular C. mast colonization and beneficial local immunity. While this constitutes proof-of-concept that a bona fide ocular microbiome that tunes immunity can exist at the ocular surface, there remain numerous unanswered questions to be addressed before microbiome-modulating therapies may be successfully developed. Here, the authors will briefly outline what is currently known about the local ocular microbiome as well as microbiomes associated with other sites, and how those sites may play a role in ocular surface immunity. Understanding how commensal microbes affect the ocular surface immune homeostasis has the potential revolutionize how we think about treating ocular surface disease.

show abstract

“…Ocular allergy occurs in 15%–25% of the general population. 1 , 2 In other countries, antigens include grass, 3 differing from those that cause allergic conjunctivitis in Japan. 4 , 5 Japanese cedar pollinosis is a common disease with an age-adjusted estimated prevalence of 19.4% in Japan 4 and is considered to be a national affiction.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment

Mizoguchi

Ozaki

Ogino

2017

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy and safety of 0.05% epinastine and 0.1% olopatadine eye drop preparations as seasonal and preseasonal treatments in patients with seasonal allergic conjunctivitis (SAC).Subjects and methodsThis was a prospective, randomized, case-control study involving two institutions. The subjects were patients diagnosed with SAC at two institutions between February and March in 2014. To examine the clinical effects of seasonal treatment, 0.05% epinastine and 0.1% olopatadine were administered, and their effects were investigated every 2 weeks (Stage 1). To evaluate the clinical effects of preseasonal therapy, in January 2015, the same eye drop preparations as adopted in Stage 1 were administered to patients who had participated in Stage 1 and provided consent to participate in this study, and their effects were investigated every month (Stage 2).ResultsIn Stage 1, the 0.05% epinastine group consisted of 43 patients, and the 0.1% olopatadine group consisted of 42 patients. There were significant improvements in the total symptom and objective finding scores at each time point after administration in comparison with those before its baseline, but there were no significant differences between the two groups. In Stage 2, the 0.05% epinastine group consisted of 15 patients, and the 0.1% olopatadine group consisted of 14 patients. The rate of change in the total symptom score in comparison with that at the baseline of preseasonal treatment was significantly higher in the 0.1% olopatadine group 1 month after the start of treatment, suggesting symptom deterioration (P=0.025). There was no significant difference in the rate of change in the total objective finding score between the two groups.ConclusionSeasonal treatment with 0.05% epinastine or 0.1% olopatadine was equally effective for patients with allergic conjunctivitis. However, for preseasonal therapy, 0.05% epinastine was more effective than 0.1% olopatadine.

show abstract

Emerging therapeutics for ocular surface disease

Cited by 15 publications

References 36 publications

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment

Contact Info

Product

Resources

About